313 POTENTIAL COST SAVINGS OF ACTIVE SURVEILLANCE OVER UP FRONT TREATMENT OF PROSTATE CANCER FOR THE US HEALTHCARE SYSTEM

Background: Venous leg ulcers (VLUs) present a significant economic burden on the US healthcare system and payers (US$14.9 billion). Aim: To evaluate the quality of life (QoL) of patients with VLUs; to analyze the limitations of standard of care (SOC) for VLUs; and to explain how using bilayered living cellular construct (BLCC) with SOC for treatment of VLUs can help heal more VLUs faster (than using SOC alone) as well as help improve QoL and help reduce the burden on the US healthcare system and payers. Materials & methods: This is a review study. The search was conducted in February 2020 by way of electronic databases to find relevant articles that provided information related to QoL of patients with VLUs, limitations of SOC for VLUs and economic analyses of using BLCC for treatment of VLUs. Results: VLUs impact patients’ physical, functional and psychological status and reduce QoL. A total 75% of VLU patients who used SOC alone failed to achieve healing in a timely fashion, which led to increased healthcare costs and healthcare resource utilization. Although the upfront cost is high, the greater effectiveness of BLCC offsets the added cost of the product during the time period of the studies. Therefore, BLCC helps to improve the QoL of VLU patients. As an example, for every 100 VLU patients in a healthcare plan, the use of BLCC can create cost savings of US$1,349,829.51. Conclusion: Payers’ coverage of BLCC results in reduction of the overall medical cost for treating VLU patients.

Download Full-text

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

BMC Health Services Research ◽

10.1186/s12913-019-4680-2 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 5

Author(s):

Kerry Mansell ◽

Hishaam Bhimji ◽

Dean Eurich ◽

Holly Mansell

Keyword(s):

Insulin Glargine ◽

Retrospective Analysis ◽

Healthcare System ◽

Healthcare Providers ◽

Cost Savings ◽

Sensitivity Analyses ◽

Potential Cost ◽

Biologic Drugs ◽

Cross Sectional ◽

Time Period

Abstract Background In 2014 and 2015, biosimilars for the drugs filgrastim, infliximab, and insulin glargine were approved for use in Canada. The introduction of biosimilars in Canada could provide significant cost savings for the Canadian healthcare system over originator biologic drugs, however it is known that the use of biosimilars varies widely across the world. The aim of this study was to estimate the use of biosimilars in Canada and potential cost-savings from their use. Methods We performed a retrospective analysis of Canadian drug purchases for filgrastim, infliximab, and insulin glargine from July 2016 to June 2018. This was a cross-sectional study and the time horizon was limited to the study period. As a result, no discounting of effects over time was included. Canadian drugstore and hospital purchases data, obtained from IQVIA™, were used to estimate the costs per unit and unit volume for biosimilars and originator biologic drugs within each province. Potential cost-savings were calculated as a product of the units of reference originator product purchased and the cost difference between the originator biologic and its corresponding biosimilar. Results The purchase of biosimilars varied by each province in Canada, ranging from a low of 0.1% to a high of 81.6% of purchases. In total, $1,048,663,876 Canadian dollars in savings could have been realized with 100% use of biosimilars over the originator products during this 2 year time period. The potential savings are highest in the province of Ontario ($349 million); however, even in smaller markets (PEI and Newfoundland), $28 million could have potentially been saved. Infliximab accounted for the vast majority of the potential cost-savings, whereas the purchases of the biosimilar filgrastim outpaced that of the originator drug in some provinces. In sensitivity analyses assuming only 80% of originator units would be eligible for use as a biosimilar, $838 million dollars in cost savings over this two-year time period would still have been realized. Conclusions The overall use of biosimilar drugs in Canada is low. Policy makers, healthcare providers, and patients need to be informed of potential savings by increased use of biosimilars, particularly in an increasingly costly healthcare system.

Download Full-text

PD03-03 REAL-WORLD ACTIVE SURVEILLANCE IMPLEMENTATION IN BLACK MEN WITH PROSTATE CANCER IN THE US

The Journal of Urology ◽

10.1097/ju.0000000000001967.03 ◽

2021 ◽

Vol 206 (Supplement 3) ◽

Author(s):

Bashir Al Hussein Al Awamlh ◽

Patrick Lewicki ◽

Spyridon Basourakos ◽

Xian Wu ◽

Jim Hu ◽

...

Keyword(s):

Prostate Cancer ◽

Black Men ◽

Active Surveillance ◽

Real World ◽

The Us

Download Full-text

Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in Switzerland

Epidemiology and Infection ◽

10.1017/s0950268816001618 ◽

2016 ◽

Vol 145 (4) ◽

pp. 627-641 ◽

Cited By ~ 8

Author(s):

C. SCHMUTZ ◽

D. MÄUSEZAHL ◽

P. J. BLESS ◽

C. HATZ ◽

M. SCHWENKGLENKS ◽

...

Keyword(s):

Healthcare System ◽

Acute Gastroenteritis ◽

Healthcare Costs ◽

Cost Savings ◽

Individual Treatment ◽

Health Statistics ◽

Potential Cost ◽

The Past ◽

Test Result ◽

Human Campylobacteriosis

SUMMARYRising numbers of campylobacteriosis case notifications in Switzerland resulted in an increased attention to acute gastroenteritis (AG) in general. Patients with a laboratory-confirmed Campylobacter infection perceive their disease as severe and around 15% of these patients are hospitalized. This study aimed at estimating healthcare costs due to AG and campylobacteriosis in Switzerland. We used official health statistics, data from different studies and expert opinion for estimating individual treatment costs for patients with different illness severity and for extrapolating overall costs due to AG and campylobacteriosis. We estimated that total Swiss healthcare costs resulting from these diseases amount to €29–45 million annually. Data suggest that patients with AG consulting a physician without a stool diagnostic test account for €9·0–24·2 million, patients with a negative stool test result for Campylobacter spp. for €12·3 million, patients testing positive for Campylobacter spp. for €1·8 million and hospitalized campylobacteriosis patients for €6·5 million/year. Healthcare costs of campylobacteriosis are high and most likely increasing in Switzerland considering that campylobacteriosis case notifications steadily increased in the past decade. Costs and potential cost savings for the healthcare system should be considered when designing sectorial and cross-sectorial interventions to reduce the burden of human campylobacteriosis in Switzerland.

Download Full-text

Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US

JAMA Network Open ◽

10.1001/jamanetworkopen.2020.31349 ◽

2020 ◽

Vol 3 (12) ◽

pp. e2031349

Author(s):

Samuel L. Washington ◽

Chang Wook Jeong ◽

Peter E. Lonergan ◽

Annika Herlemann ◽

Scarlett L. Gomez ◽

...

Keyword(s):

Prostate Cancer ◽

Active Surveillance ◽

Regional Variation ◽

Low Risk ◽

The Us ◽

Risk Prostate Cancer ◽

Low Risk Prostate Cancer

Download Full-text

MP23-03 TEMPORAL CHANGES IN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MEN WITH PROSTATE CANCER ELECTING FOR ACTIVE SURVEILLANCE IN THE US

The Journal of Urology ◽

10.1097/ju.0000000000000856.03 ◽

2020 ◽

Vol 203 ◽

pp. e338

Author(s):

Bashir Al Hussein Al Awamlh* ◽

Xiaoyue Ma ◽

Peter Cai ◽

Neal Patel ◽

Spyros Basourakos ◽

...

Keyword(s):

Prostate Cancer ◽

Active Surveillance ◽

Clinical Characteristics ◽

Temporal Changes ◽

The Us

Download Full-text

Biosimilars in Oncology

Oncology & Hematology Review (US) ◽

10.17925/ohr.2016.12.01.22 ◽

2016 ◽

Vol 12 (01) ◽

pp. 22 ◽

Cited By ~ 2

Author(s):

Andrew D Zelenetz ◽

Keyword(s):

Patient Outcomes ◽

Healthcare Expenditure ◽

Reference Product ◽

Cost Savings ◽

European Medicines Agency ◽

Regulatory Pathway ◽

Potential Cost ◽

Clinician Education ◽

The Us ◽

Structural Differences

The escalating cost of cancer care is placing an increasing burden on healthcare systems worldwide, largely a result of expensive biologic therapies. With the patents on many biologics expiring, interest in biosimilars is rising. Biosimilars of biologic agents used for cancer treatment and supportive care are making their appearance in the US; this article therefore aims to increase understanding of the biosimilars concept. Biosimilars are very comparable to their reference products, but because of their size and complexity, are not identical. However, the inherent structural differences between biologics and their reference products may not translate to clinically meaningful differences in efficacy and safety. Biosimilars offer potential cost savings but present a challenge in terms of establishing a regulatory pathway. Regulatory approval requires comparative analytical and clinical studies in order to characterize and demonstrate the absence of clinically meaningful differences between biosimilars and their reference products. Initial approval may not include interchangeability, as additional evidence may be required before a biosimilar can be designated interchangeable with its reference product. A framework for the approval of biosimilars was established by the European Medicines Agency (EMA) in 2006 with the first biosimilar approved in April, 2006. Thus, the experience in Europe provides valuable insights into the use of biosimilars. The widespread use of biosimilars has the potential to reduce healthcare expenditure, as well as improving patient access without compromising patient outcomes, but clinician education and acceptance is crucial.

Download Full-text

Localized Prostate Cancer—What the Medical Oncologist Needs to Know

Oncology & Hematology Review (US) ◽

10.17925/ohr.2011.07.1.50 ◽

2011 ◽

Vol 07 (01) ◽

pp. 50

Author(s):

Aditya Bardia ◽

Michael A Carducci ◽

◽

Keyword(s):

Prostate Cancer ◽

Active Surveillance ◽

Specific Antigen ◽

Localized Prostate Cancer ◽

Medical Oncologist ◽

Adjuvant Therapies ◽

Medical Oncologists ◽

The Us ◽

Prostate Cancers

Prostate cancer is the most commonly diagnosed cancer among men and the second leading cause of cancer-related deaths among men in the US. In the post-prostate specific antigen (PSA) era, about 85% of all prostate cancers diagnosed are clinically localized prostate cancers. Most cancers are diagnosed in asymptomatic men, and T1c (stage I) is the most commonly diagnosed stage of prostate cancer. Consequently, medical oncologists are increasingly being asked to participate in multidisciplinary prostate cancer clinics and provide recommendations on localized prostate cancer, particularly related to active surveillance as well as neoadjuvant and adjuvant therapies such as androgen deprivation therapy (ADT) and chemotherapy. This article reviews the potential role of the medical oncologist as a team member in the management of localized prostate cancer. The role of active surveillance as well as neo-adjuvant and adjuvant therapies such as ADT and chemotherapy is discussed in detail. The long-term adverse effects of ADT and potential supportive measures are also reviewed.

Download Full-text